Medtech Industry Veteran joins GelSana as Chief Commercial Officer 

(AURORA, CO) – January 09, 2026 – GelSana Therapeutics, Inc. (“GelSana”), a wound care company developing novel polymer-based dressings to accelerate healing, today announced that Donald Gregg has joined the company as Chief Commercial Officer (CCO). In this new role, Gregg will lead all commercial strategy and execution as GelSana prepares for the launch of its first product, Cleragel™.

Gregg is a transformative commercial leader with more than 25 years’ experience leading high-performing global commercialization organizations. He has led med-tech and technology businesses and launched several products in both start-ups and large multi-national corporations. Most recently, Gregg served as President of Zynex Monitoring Solutions, Inc., where he built and led all functions for the company’s non-invasive patient monitoring portfolio. Prior to Zynex, he held leadership roles as Smith Medical’s Vice President and General Manager of Infusion Systems and Medtronic’s Senior Director of Product, Marketing and Business Development, Patient Monitoring. “GelSana is entering a pivotal phase as we commercialize our first product, Cleragel.” said Melissa Krebs, CEO and Founder of GelSana. “Donald’s track record in building high-performing commercial teams and scaling novel medical technologies is an ideal fit with our mission to transform wound healing for patients with chronic and hard-to-treat wounds.”​

“I am excited to join GelSana at this important moment in the company’s growth,” said Donald Gregg. “GelSana’s polymer platform and first product Cleragel have the potential to meaningfully change the standard of care in wounds by reducing inflammation and improving healing trajectories. I look forward to supporting GelSana to deliver these innovative products  to patients, providers, and health systems.”​​

About GelSana 

GelSana is a biomaterials company developing next-generation polymer-based dressings designed to reduce inflammation, improve wound closure, and enhance patient comfort in chronic and acute wounds. GelSana’s first product, Cleragel, will be commercially available in Q1 2026. GelSana is headquartered in Aurora, Colorado.

For media inquiries, please contact:

Melissa Krebs, Ph.D.
CEO and Founder
GelSana Therapeutics, Inc.
mdkrebs@gelsanatherapeutics.com